Compare · A vs BRKR
A vs BRKR
Side-by-side comparison of Agilent Technologies Inc. (A) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $38.26B, about 4.3x BRKR ($8.87B).
- Over the past year, A is up 12.4% and BRKR is up 40.9% - BRKR leads by 28.5 points.
- A has been more active in the news (19 items in the past 4 weeks vs 10 for BRKR).
- A has more recent analyst coverage (25 ratings vs 22 for BRKR).
- Company
- Agilent Technologies Inc.
- Bruker Corporation
- Price
- $135.50+2.17%
- $57.28+1.82%
- Market cap
- $38.26B
- $8.87B
- 1M return
- +17.21%
- +29.71%
- 1Y return
- +12.41%
- +40.88%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 19
- 10
- Recent ratings
- 25
- 22
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest A
- New insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)
- President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)
- Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
- Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
- Director Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)
- SEC Form 10-Q filed by Agilent Technologies Inc.
- SEC Form SD filed by Agilent Technologies Inc.
- Agilent upgraded by BofA Securities with a new price target
- Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
- Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
Latest BRKR
- Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
- Amendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
- Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bernard Thierry was granted 2,886 shares (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $87,800 worth of shares (2,000 units at $43.90) as part of a pre-agreed trading plan (SEC Form 4)